Plain-English translation of NCT04747912 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new drug called (or InO for short) combined with standard cancer treatments for people with a specific type of acute lymphoblastic leukemia. The goal is to see if adding this medication helps patients reach complete remission—meaning the cancer is no longer detectable even with very sensitive tests—more quickly than standard treatment alone.
While standard treatments for this type of leukemia help many patients, doctors want to know if this medication can improve results by helping more patients reach deeper remission faster. This could lead to better long-term survival and outcomes for newly diagnosed patients.
You likely qualify if…
You likely don't qualify if…
You would receive two phases of treatment over 60 days: an induction phase (28 days) and a consolidation phase (28 days). During this time, you'll take as a daily pill, receive , and get intravenous doses of the new medication on specific days. You'll also receive spinal tap injections of . Your treatment in the second phase may be adjusted based on how well you respond to the first phase. You'll have regular clinic visits, blood tests, and imaging to monitor your progress.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States